NCT05596617 is a NA clinical trial of Oral bedtime melatonin in Severe Covid-19, sponsored by Hospital San Carlos, Madrid.

Who is sponsoring NCT05596617?

NCT05596617 is sponsored by Hospital San Carlos, Madrid.

What drugs are being tested in NCT05596617?

Interventions in NCT05596617: Oral bedtime melatonin.

What condition does NCT05596617 study?

NCT05596617 studies Severe Covid-19.

Is NCT05596617 still recruiting?

NCT05596617 is currently completed. Last updated 27 October 2022.

Last reviewed 2022-10-27 · How we verify

NCT05596617

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety and Efficacy of Medications COVID-19

Completed NA Last updated 27 October 2022

What this trial tests

NA trial testing Oral bedtime melatonin in Severe Covid-19 in 335 participants. Completed in 31 March 2022.

Timeline

22 April 2020

Primary endpoint
31 May 2021

31 March 2022

Quick facts

Lead sponsor	Hospital San Carlos, Madrid
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	335
Start date	22 April 2020
Primary completion	31 May 2021
Estimated completion	31 March 2022
Sites	1 location across Spain

Drugs / interventions tested

Oral bedtime melatonin — full drug profile →

Conditions studied

Severe Covid-19 — all drugs for Severe Covid-19 →

Sponsor

Hospital San Carlos, Madrid

Who can join

Eligibility, any sex, with Severe Covid-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

We performed a quasi-experimental open-label pragmatic study alternating standard of care (SOC) and oral bedtime melatonin (OBM) at different high doses over 4 consecutive time periods enrolling all consecutive RT-PCR SARS-CoV-2 severe Covid-19 admissions.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Hospital San Carlos, Madrid trials

Trials by the same sponsor.

NCT06310941 — Mechanical Insufflation-exsufflation and Hypertonic Saline in Nosocomial Bacterial Respiratory Tract Infection · NA · not yet recruiting
NCT07002658 — Clinical Impact of Surgical Wound Morbidity According to the Type of Saphenous Vein Harvesting Technique (Endoscopic vs. · NA · not yet recruiting
NCT06113939 — Prevention of Infection of the Respiratory Tract Through Application of Non-Invasive Methods of Secretion Suctioning · NA · not yet recruiting
NCT06156059 — Oral Bedtime Melatonin in Critically Ill Patients · Phase 4 · unknown
NCT07390175 — Ablation of Human Cardiac Fibrillation Based on Models of Hierarchical Organization of Tissue Excitation · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05596617 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hospital San Carlos, Madrid
Last refreshed: 27 October 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05596617.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing